| Gene/Disease Pair: | KIF1B : Hereditary pheochromocytoma-paraganglioma |
| HGNC:16636 | OrphaNet: 29072 | OMIM:605995 | |
| Mode of Inheritance: | Autosomal dominant inheritance (HP:0000006) |
Genetic Evidence
|
Case-Level Data
|
Evidence Type | Case Information Type | Guidelines | Scores | PMIDs/Notes | ||||||
| Default | Range | Max | Points | Tally | ||||||||
Variant Evidence
|
Autosomal Dominant or X-linked Disorder | Variant is de novo | 2 | 0-3 | 12 | |||||||
| Proband with predicted or proven null variant | 1.5 | 0-2 | 10 | 4.0 | 4 |
Welander J et al. 2014 Jul (PMID:24694336); Yeh IT et al. 2008 Oct (PMID:18726616); Schlisio S et al. 2008 Apr 1 (PMID:18334619);
|
||||||
| Proband with other variant type with some evidence of gene impact | 0.5 | 0-1.5 | 7 | 0.0 | 0 | |||||||
| Autosomal Recessive Disease | Two variants in trans and at least one de novo or a predicted/proven null variant | 2 | 0-3 | 12 | ||||||||
| Two variants (not predicted/proven null) with some evidence of gene impact in trans | 1 | 0-1.5 | ||||||||||
| Segregation Evidence | Evidence of segregation in one or more families | LOD Score Examples | 3 | 5 | 0-7 | 7 | ||||||
| 2 | 4 | |||||||||||
| 1.5 | 3 | |||||||||||
| 1 | 1.5 | |||||||||||
Case-Control Data
|
Case-Control Study Type | Case-Control Quality Criteria | Guidelines | Scores | PMIDs/Notes | |||||||
| Points/Study | Max | Points | Tally | |||||||||
| Single Variant Analysis | 1. Variant Detection Methodology 2. Power 3. Bias and confounding 4. Statistical Significance |
0-6 | 12 | |||||||||
| Aggregate Variant Analysis | 0-6 | 12 | ||||||||||
| Total Genetic Evidence Points (Maximum 12) | 4 | |||||||||||
Experimental Evidence
|
Evidence Category | Evidence Type | Guidelines | Scores | PMIDs/Notes | |||||||
| Default | Range | Max | Points | Tally | ||||||||
| Function | Biochemical Function | 0.5 | 0 - 2 | 2 | 2.0 | 2 |
Chen ZX et al. 2014 Apr (PMID:24469107); Schlisio S et al. 2008 Apr 1 (PMID:18334619); Welander J et al. 2012 Dec 15 (PMID:23010473); |
|||||
| Protein Interaction | 0.5 | 0 - 2 | ||||||||||
| Expression | 0.5 | 0 - 2 | ||||||||||
| Functional Alteration | Patient cells | 1 | 0 - 2 | 2 | 0.0 | 0 | ||||||
| Non-patient cells | 0.5 | 0 - 1 | ||||||||||
| Models & Rescue | Animal model | 2 | 0 - 4 | 4 | 0.0 | 0 | ||||||
| Cell culture model system | 1 | 0 - 2 | ||||||||||
| Rescue in animal model | 2 | 0 - 4 | ||||||||||
| Rescue in engineered equivalent | 1 | 0 - 2 | ||||||||||
| Total Experimental Evidence Points (Maximum 6) | 2 | |||||||||||
| Assertion criteria | Genetic Evidence (0-12 points) | Experimental Evidence (0-6 points) |
Total Points (0-18) |
Replication Over Time (Y/N) | ||
| Description | Case-level, family segregation, or case-control data that support the gene-disease association | Gene-level experimental evidence that support the gene-disease association | Sum of Genetic & Experimental Evidence |
> 2 pubs w/ convincing evidence over time (>3 yrs) | ||
| Assigned Points | 4 | 2 | 6 | YES | ||
| CALCULATED CLASSIFICATION | LIMITED | 1-6 | ||||
| MODERATE | 7-11 | |||||
| STRONG | 12-18 | |||||
| DEFINITIVE | 12-18 AND replication over time | |||||
| Valid contradictory evidence (Y/N)* |
||||||
| CALCULATED CLASSIFICATION (DATE) |
LIMITED
06/22/2017
|
|||||
| EXPERT CURATION (DATE) |
LIMITED
06/22/2017
Assertion made by the Hereditary Cancer Working Group.
|
|||||